Ophthalmic use of alpha adrenergic blocking agents

Details Ophthalmic use of alpha adrenergic blocking agents Ophthalmic use of alpha adrenergic blocking agents

A - Human Necessities

61

K

A61K 31/138 (2006.01) A61K 9/00 (2006.01) A61K 31/00 (2006.01) A61K 31/222 (2006.01) A61K 31/415 (2006.01) A61K 31/4168 (2006.01) A61K 31/417 (2006.01) A61K 31/4174 (2006.01) A61K 31/55 (2006.01) A61K 45/06 (2006.01) A61P 27/02 (2006.01)

Patent

CA 2398158

Disclosed are methods and compositions for inhibiting undesirable visual anomalies commonly experienced by individuals who have undergone refractive eye surgery, including photophobia, glare, secondary images and haloing. In particular, the disclosure provides for topically applying an ophthalmic solution to the eye wherein the ophthalmic solution contains a therapeutically effective amount of one or more alpha adrenergic blocking agents, preferably thymoxamine. The disclosure further provides for an ophthalmic solution containing one or more alpha adrenergic blocking agents in a physiologically acceptable carrier, which can be administered to a subject at an effective dose to be therapeutically effective in concentration and rate of release. An ophthalmic solution for inhibiting one or more visual anomalies experienced by an individual who has undergone refractive eye surgery containing a therapeutically effective amount of one or more alpha adrenergic blocking agents in combination with one or more anti-irritant agents and/or one or more anti-inflammatory agents is also disclosed.

L'invention concerne des méthodes et des compositions permettant d'inhiber des anomalies visuelles indésirables, notamment photophobie, éblouissement, images secondaires, et effet de halo, communément rencontrées par des individus ayant subis une chirurgie oculaire de réfraction. L'invention consiste, en particulier, à appliquer une solution ophtalmique sur l'oeil de manière topique, ladite solution ophtalmique contenant une quantité thérapeutiquement efficace d'au moins un agent bloquant adrénergique alpha, de préférence la thymoxamine. L'invention concerne également une solution ophtalmique contenant au moins un agent bloquant adrénergique alpha dans un milieu physiologiquement acceptable, pouvant être administré à un sujet en dose efficace dont la concentration et la rapidité de libération sont thérapeutiquement efficaces. L'invention concerne enfin une solution ophtalmique permettant d'inhiber au moins une anomalie visuelle rencontrée par un individu ayant subi une chirurgie oculaire de réfraction, contenant une quantité thérapeutiquement efficace d'au moins un agent bloquant adrénergique alpha associé à au moins un agent anti-irritant et/ou à au moins un agent anti-inflammatoire.

Affiliated with

Also associated with

Rating

Ophthalmic use of alpha adrenergic blocking agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ophthalmic use of alpha adrenergic blocking agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ophthalmic use of alpha adrenergic blocking agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1910722